DNA vs ETRA
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
DNA · Ginkgo Bioworks$7.46 ▼ 9.02%
ETRA · ELECTRA THERAPEUTICS INC$8.11 ▼ 9.28%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- DNA -5.3%
- ETRA -38.8%
Head to head
| Metric | DNA | ETRA |
|---|---|---|
| Price | $7.46 | $8.11 |
| Change today | ▼ 9.02% | ▼ 9.28% |
| Market cap | $483.59M | $509.85M |
| Return, 3 months | +10.0% | – |
| Return, year to date | -10.2% | – |
| Return, 1 year | -8.7% | – |
| P/E (TTM) | – | – |
| P/B | 1.2 | 1.3 |
| P/E percentile vs own 5y | 30th | 71st |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | -5.7% | – |
| Net profit growth (YoY) | +49.2% | -150.0% |
| Gross margin | 69.8% | – |
| Operating margin | -202.5% | – |
| Net margin | -192.0% | – |
| Return on equity | -52.7% | – |
| Analyst target vs. price | -33.0% | +302.8% |
| Analyst buy share | 0% | 100% |
| RSI (14) | 37 | 43 |
| 30-day volatility | 137.1% | 96.0% |
| Max drawdown, 1 year | -50.2% | -47.5% |
| Trend read | Strong downtrend | Strong downtrend |
| Analyst consensus | Sell | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- ETRA is the largest of the group by market value.
- ETRA has been the calmest stock over the last 30 days.